VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). The technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring.
According to the press release, the published research describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce greater than 99% pure ctDNA sequencing datasets. Early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, the company said.
Volition is advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.
This development is significant because liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, potentially enabling earlier cancer detection and more effective treatment monitoring. The high purity of ctDNA achieved by Capture-Seq could improve the sensitivity and specificity of cancer detection, reducing false positives and enabling the detection of early-stage cancers that are currently difficult to identify.
The announcement comes as the liquid biopsy market is growing rapidly, with increasing demand for non-invasive diagnostic tools. If Capture-Seq proves successful in larger validation studies, it could become a key technology in the fight against cancer, potentially saving lives and improving outcomes for patients worldwide.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, it is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/nuJEs.
